Published in Hepatitis Weekly, June 8th, 1998
The studies with lamivudine, an oral antiviral treatment under development by Glaxo Wellcome Inc., showed that the drug offers benefits that can be sustained for as long as two years in patients with chronic hepatitis B.
Currently, established treatments for hepatitis B are designed to boost the immune system. The goal of antiviral treatment with drugs such as lamivudine is to inhibit HBV replication, thus leading to reduced inflammatory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.